Real-world Study of Aflibercept 8 mg in nAMD to Assess Efficacy and Safety
An observational study is underway to evaluate the effectiveness and safety of aflibercept 8 mg in nAMD patients.
Asset / Drug
Drug and asset intelligence for Aflibercept with 3 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
Aflibercept 8 mg is being evaluated in a study for its effectiveness in extending injection intervals for patients with refractory exudative age-related macular degeneration.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.